Thus, experimental validation remains essential to confirm that computationally predicted synergies translate into clinically meaningful outcomes, such as enhanced efficacy or reduced toxicity, in HER2-positive breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.